iOnctura

iOnctura is a clinical-stage biopharmaceutical company combating neglected and hard-to-treat cancers with precision oral small molecules that target cancers in novel ways. The bold new treatments extend lives and improve healthspans, changing the outlook for patients and their families. Two therapeutic candidates have progressed into mid-stage clinical development: roginolisib is the first allosteric modulator of PI3K and cambritaxestat is the only autotaxin inhibitor in clinical development to treat cancer

Oncology,drug development,and clinical development

Ionctura operates in the Biotechnology research industry.

Ionctura's revenue is 11m - 100m

Ionctura has 11 - 50 employees.